Co-Authors
This is a "connection" page, showing publications co-authored by SAROJ VADHAN and SHREYASKUMAR PATEL.
Connection Strength
0.485
-
Prognostic significance of elevated D-dimer for survival in patients with sarcoma. Am J Clin Oncol. 2012 Oct; 35(5):462-7.
Score: 0.112
-
Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med. 2010 Sep 21; 153(6):358-67.
Score: 0.098
-
Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003 Aug 15; 21(16):3158-67.
Score: 0.060
-
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998 Jun; 21(3):317-21.
Score: 0.042
-
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol. 1997 Jun; 15(6):2378-84.
Score: 0.039
-
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997 May 01; 126(9):673-81.
Score: 0.039
-
In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood. 1995 Sep 15; 86(6):2098-105.
Score: 0.034
-
Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol. 1994 Apr; 12(4):715-24.
Score: 0.031
-
Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1994 Jan; 22(1):100-2.
Score: 0.031